Catalog6 refs
Retatrutide (LY3437943)
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
CirculationSkin
Overview
Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications. Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation.
Primary Uses
Weight loss (17.5% at 24 weeks, 24.2% at 48 weeks)
Sustained weight management
Type 2 diabetes glycemic control (HbA1c reduction up to 2.16%)
Insulin sensitivity improvement
Lipid improvement (non-HDL cholesterol reduction up to 26.9%, triglycerides up to 40.6%)
Blood pressure optimization
Hepatic fat reduction (up to 82%)
Cardiovascular benefits
Protocol Reference
Dose
0.5mg starting, titrate up to 8-12mg weekly
Frequency
Once weekly (same day each week)
Half-life
~6 days
Route
Subcutaneous injection (abdomen, thigh, or upper arm with site rotation)
Evidence
Extensively Studied
Research Models
Human
Also in Metabolic